Clinical Trials
688 trialsNCT01107522 2025-09-09
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Tactical Therapeutics, Inc.
Phase 1 Unknown
NCT04637763 2025-03-24
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Caribou Biosciences, Inc.
Phase 1 Unknown
NCT02716012 2025-03-10
OUTREACH
Mina Alpha Limited
Phase 1 Unknown
NCT06371534 2025-02-11
A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT06254807 2024-12-19
CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
Phase 1 Unknown
NCT04660929 2024-12-18
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
Phase 1 Unknown
NCT06724835 2024-12-09
Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T)
Shenzhen Celconta Life Science Co., Ltd.
Phase 1 Unknown
NCT05650242 2024-11-08
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors
Shandong Boan Biotechnology Co., Ltd
Phase 1 Unknown
NCT04977167 2024-10-10
Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma
HitGen Inc.
Phase 1 Unknown
NCT06196762 2024-10-10
Phase I of XKH002 Injection in Patients
Zhejiang Kanova Biopharmaceutical Co., LTD
Phase 1 Unknown
NCT05076552 2024-08-01
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer
Tachyon Therapeutics, Inc.
Phase 1 Unknown
NCT06533605 2024-08-01
Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 1 Unknown
NCT06526832 2024-07-30
A Phase 1 Study of BST02 in Treating Locally Advanced Liver Cancer
BioSyngen Pte Ltd
Phase 1 Unknown
NCT06199908 2024-07-26
AMT-562 in Patients With Selected Advanced Solid Tumors
Multitude Therapeutics Inc.
Phase 1 Unknown
NCT06237491 2024-07-24
The Safety and Dosimetry Study of 177Lu-LNC1003 Injection
Yantai LNC Biotechnology Singapore PTE. LTD.
Phase 1 Unknown
NCT06256055 2024-07-24
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
Phase 1 Unknown
NCT06094777 2024-06-13
A Study of HY-0102 in Patients With Advanced Solid Tumors
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1 Unknown
NCT05457010 2024-06-12
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Arcellx, Inc.
Phase 1 Unknown
NCT06433726 2024-05-30
A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors
Chengdu Baiyu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05605197 2024-05-28
U87 CART in Treatment of Advanced Solid Tumor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Unknown
NCT05564858 2024-05-17
A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05650580 2024-05-14
TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors
Tarapeutics Science Inc.
Phase 1 Unknown
NCT05751356 2024-05-14
TR128 in Patients With Advanced Solid Tumors
Tarapeutics Science Inc.
Phase 1 Unknown
NCT05354102 2024-05-07
A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128
Biomica Ltd.
Phase 1 Unknown
NCT06384482 2024-04-25
SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma
Shanghai Simnova Biotechnology Co.,Ltd.
Phase 1 Unknown
NCT05989724 2024-04-24
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Qurgen Inc.
Phase 1 Unknown
NCT06172322 2024-04-23
A Phase Ib/â…¡ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 1 Unknown
NCT05700084 2024-04-19
Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1 Unknown
NCT05483530 2024-04-16
A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1 Unknown
NCT05606380 2024-04-16
A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma
Shanghai Henlius Biotech
Phase 1 Unknown
NCT06368960 2024-04-16
BM201-1001
InnoBM Pharmaceuticals Co., Ltd.
Phase 1 Unknown
NCT04032964 2024-04-08
DOXO75
Philogen S.p.A.
Phase 1 Unknown
NCT06348290 2024-04-04
Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects
Jemincare
Phase 1 Unknown
NCT05521022 2024-04-03
AT02-001
Attralus, Inc.
Phase 1 Unknown
NCT06247657 2024-04-03
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours
Shanghai Best-Link Bioscience, LLC
Phase 1 Unknown
NCT06344715 2024-04-03
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
SL VAXiGEN
Phase 1 Unknown
NCT05311618 2024-04-01
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Phase 1 Unknown
NCT05394168 2024-04-01
A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1 Unknown
NCT05193721 2024-03-20
A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Unknown
NCT05037149 2024-03-18
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
Sirnaomics
Phase 1 Unknown
NCT05646758 2024-03-18
A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05783570 2024-03-15
To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307
Eutilex
Phase 1 Unknown
NCT04671875 2024-03-13
A Clinical Study of MIL93 in Solid Tumors.
Beijing Mabworks Biotech Co., Ltd.
Phase 1 Unknown
NCT05475210 2024-03-13
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
Molecular Targeting Technologies, Inc.
Phase 1 Unknown
NCT05798026 2024-03-13
A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy
Eutilex
Phase 1 Unknown
NCT06139536 2024-03-13
Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients
Bio-Thera Solutions
Phase 1 Unknown
NCT05103046 2024-03-12
First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
1200 Pharma, LLC
Phase 1 Unknown
NCT05872867 2024-03-12
MK-3475-E90
Wellmarker Bio
Phase 1 Unknown
NCT05894421 2024-03-12
TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT06307093 2024-03-12
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
R-Pharm
Phase 1 Unknown